Mesna as a nonvitamin intervention to lower plasma total homocysteine concentration: implications for assessment of the homocysteine theory of atherosclerosis.
Elevated plasma total homocysteine is independently associated with atherosclerosis. Recent randomized trials show that vitamins lower total homocysteine but do not prevent cardiovascular events, suggesting the need for nonvitamin therapies to evaluate whether a causative relationship exists. Mesna (sodium 2-mercaptoethanesulfonate) is a thiol-containing drug capable of liberating homocysteine bound by disulfide bonds to proteins, facilitating its excretion. The effect of oral mesna on total homocysteine has not been evaluated and was the objective of this study. Eleven healthy volunteers received vehicle or 10 mg/kg mesna in random order, after which serial blood and urine samples were collected over 4 hours. Plasma total homocysteine decreased by 24.2% (P < .0001) following mesna. Urinary homocysteine excretion was significantly greater with mesna (3.9 +/- 2.4 mumol) compared to vehicle (0.4 +/- 0.1 mumol), P < .01. Oral mesna decreases plasma total homocysteine and is a potential nonvitamin treatment for assessing the homocysteine theory of atherosclerosis.
Urquhart
Bradley L
BL
Division of Clinical Pharmacology, Department of Medicine and Physiology, University of Western Ontario and Lawson Health Research Institute, London, Ontario, Canada.
Freeman
David J
DJ
Spence
J David
JD
House
Andrew A
AA
D000328:Adult; D050197:Atherosclerosis / Q000097:blood*; D018592:Cross-Over Studies; D005260:Female; D006710:Homocysteine / Q000097:blood* / Q000652:urine; D006801:Humans; D008297:Male; D015080:Mesna / Q000493:pharmacokinetics / Q000494:pharmacology*; D008875:Middle Aged; D012307:Risk Factors
D006710:Homocysteine; D015080:Mesna